Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab after SBRT or ablation for primary hepatocellular carcinoma
ChiCTR2100053415Phase 4Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: Progression-free survival, Disease control rate and 3 more. Started Dec 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100053415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053415.